Sam Liss will become the next leader of OTD as the University’s chief technology development officer and associate provost.

The Harvard Crimson provides an overview of the establishment and mission of Harvard’s Office of Technology Development as Isaac Kohlberg steps down from his leadership role.

Harvard Magazine provides an overview of Isaac Kohlberg’s accomplishments over his two decades at Harvard.

Attivare Therapeutics, a Harvard startup out of the Wyss Institute, has licensed a portfolio of immune-modulating biomaterial technologies from Harvard University that was created at the Wyss Institute, John A. Paulson School of Engineering and Applied Sciences (SEAS), Dana-Farber Cancer Institute, and Massachusetts General Hospital. This technology creates an in vivo training ground for the immune system to fight cancer more effectively and prevent infection.